Quantitation of Niraparib in Human Plasma by LC‐MS/MS
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Tien V Le und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Indazoles, Tandem Mass Spectrometry, Piperidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 14 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Polyadenosine diphosphate–ribose polymerase 1 (PARP‐1) and 2 (PARP‐2) are key DNA repair enzymes that promote single‐strand break repair via the base excision pathway. Niraparib, a PARP inhibitor, has shown clinical efficacy with the reduction of disease progression or death and progression‐free survival benefit across multiple clinical trials, leading to the Food and Drug Administration (FDA) approval for the treatment of advanced and recurrent ovarian cancers. This study presents a robust and simple 5‐min assay designed for the quantitation of the single agent niraparib in human plasma utilizing liquid chromatography–tandem mass spectrometry (LC‐MS/MS). A 50 μL volume of plasma was subjected to protein precipitation, followed by chromatographic separation using a Phenomenex Kinetex C18 column (2.6 μm, 50 × 2.1 mm) and a gradient mobile phase system consisting of 0.1% formic acid in both water and acetonitrile during a 5‐min run time. Mass spectrometric detection was achieved using a SCIEX 6500 + tandem mass spectrometer with electrospray positive‐mode ionization. With a stable isotopic internal standard, our assay met the criteria outlined by the FDA guidance for bioanalytical method validation, demonstrating robust performance within the range from 5 to 5000 ng/mL. This assay will support future clinical studies by defining niraparib pharmacokinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Women's Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
ORCID-Profile: Jan H Beumer
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Le, T. V., Taylor, S. E., Parise, R. A., Christner, S. M., Montgomery, C., Synold, T., Feng, Y., & Beumer, J. H. (2025). Quantitation of Niraparib in Human Plasma by LC‐MS/MS. Biomedical Chromatography. https://doi.org/10.1002/bmc.70181
Vancouver
Le TV, Taylor SE, Parise RA, Christner SM, Montgomery C, Synold T, et al. Quantitation of Niraparib in Human Plasma by LC‐MS/MS. Biomedical Chromatography. 2025. doi:10.1002/bmc.70181
BibTeX
@article{Le2025,
author = {Le, Tien V and Taylor, Sarah E and Parise, Robert A and Christner, Susan M and Montgomery, Cortney and Synold, Timothy and Feng, Ye and Beumer, Jan H},
title = {Quantitation of Niraparib in Human Plasma by LC‐MS/MS},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70181}
}
EUVIMED